Eyenovia, INC

Hyperion DeFi, Inc. announced new employment agreements for its CEO, CFO, and General Counsel, effective July 7, 2026, standardizing terms and enhancing severance packages.

Hyperion DeFi, Inc. held its 2026 Annual Meeting of Stockholders on June 30, 2026, where directors were elected and the appointment of its independent auditor was ratified, though a proposal to allow action by written consent failed.

Hyperion DeFi is terminating its agreements with Native Markets and Felix Foundation to reposition 800,000 HYPE tokens.

Hyperion DeFi announced record net income and adjusted EBITDA for Q1 2026, driven by strong performance in its DeFi operating segments, and has raised its full-year 2026 guidance.

Hyperion DeFi, Inc. announced the pricing of its public offering of 2,777,778 shares of common stock at $3.60 per share, expecting to raise approximately $10.0 million in gross proceeds.

Hyperion DeFi reports strong Q4 2025 growth in its DeFi operating businesses, exceeding guidance, alongside a significant net loss and a strategic move to monetize its Life Sciences segment.

Hyperion DeFi, Inc. reported a significant shift to profitability in Q1 2026, driven by substantial gains in its digital asset strategy, while its ophthalmic technology segment winds down.

Hyperion DeFi, Inc. announced a significant financial turnaround in Q3 2025, reporting net income and a substantial increase in assets driven by its strategic pivot to the Hyperliquid ecosystem.

Hyperion DeFi reports a strategic pivot to a HYPE digital token treasury, significant capital raise, and debt restructuring, alongside ongoing ophthalmic device development, despite continued net losses.

Eyenovia, Inc. reports reduced net losses in Q1 2025 while advancing its Optejet platform and exploring strategic alternatives.

Eyenovia's Q3 2024 results show continued commercialization efforts and strategic collaborations, alongside a net loss and ongoing concerns about the company's ability to continue as a going concern.

Eyenovia's Q2 2024 results show a net loss, increased R&D spending, and the reacquisition of rights to its MicroPine product.

Eyenovia, Inc. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Eyenovia is exploring strategic alternatives and cutting costs after a negative clinical trial result, raising concerns about its ability to continue as a going concern.

Eyenovia, Inc. has filed an amendment to its annual report on Form 10-K for the fiscal year ended December 31, 2023, to include previously omitted information regarding directors, executive compensation, and other corporate governance matters.

Eyenovia's annual 10-K filing details their commercialization efforts for Mydcombi and clobetasol propionate, along with strategic changes in their pipeline and manufacturing.

Director Happy David Walters acquired 58,917 shares of common stock in Hyperion Defi, Inc. on June 30, 2026.

Ellen R. Strahlman, a Director at Hyperion Defi, Inc., reported a transaction involving 58,917 shares of common stock on June 30, 2026.

Rachel Jacobson, a Director at Hyperion Defi, Inc. (HYPD), acquired 58,917 shares of common stock on June 30, 2026, as part of a restricted stock unit award.

Michael S. Geltzeiler, a Director at Hyperion DeFi, Inc. (HYPD), reported the acquisition of 58,917 shares of common stock.

Hyperion DeFi CEO Hyunsu Jung acquired 8,000 shares of common stock through open market purchases.

CEO Hyunsu Jung disposed of 40,000 shares of Hyperion DeFi, Inc. to satisfy tax obligations related to restricted stock unit vesting.

Hyperion DeFi, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 30, 2026.

Hyperion DeFi, Inc. is seeking shareholder approval for a significant increase in authorized shares and the issuance of new warrants to an institutional investor, alongside corporate governance updates, as the company reports widening net losses and concerns about its ability to continue as a going concern.

Eyenovia announces that ISS and Glass Lewis recommend stockholders vote FOR the proposed reverse stock split at the upcoming special meeting.

Eyenovia is asking stockholders to approve a reverse stock split, an increase in shares for its incentive plan, and the potential issuance of shares upon warrant exercises, as it faces delisting from the Nasdaq.

Eyenovia is holding its annual stockholder meeting on June 12, 2024, to vote on key proposals including the election of directors, ratification of the accounting firm, executive compensation, and an increase in authorized common stock.

Avenue Capital Group entities report sales of Hyperion DeFi common stock, leading to changes in their beneficial ownership percentages.

Avenue Capital Group entities updated their beneficial ownership in Hyperion DeFi, Inc., reflecting changes due to an increase in the issuer's outstanding common stock.

Hyunsu Jung, Chief Investment Officer and Director of Hyperion DeFi, Inc., has disclosed a 9.3% beneficial ownership stake in the company, acquired as an employment inducement, with potential for an additional 1,000,000 shares tied to significant market capitalization milestones.

Avenue Capital Group and its affiliates have updated their beneficial ownership in Eyenovia, Inc. to 8.53% of common stock, reflecting a change due to an increase in the issuer's outstanding shares while maintaining a 9.99% ownership blocker.

Avenue Capital Group's funds, significant investors in Eyenovia, Inc., have amended their loan agreement, cancelling previous debt conversion rights while simultaneously receiving new warrants to purchase common stock.

Avenue Capital Group entities have converted $680,098 of their $10 million loan to Eyenovia, Inc. into 404,820 shares of common stock, bringing their aggregate beneficial ownership to 9.99% due to a pre-existing blocker.

Forsakringsaktiebolaget Avanza Pension has filed a Schedule 13G, reporting beneficial ownership of 1,300,822 shares of Hyperion DeFi common stock, representing 8.58% of the class.

Forsakringsaktiebolaget Avanza Pension has disclosed a 9.88% beneficial ownership stake in Hyperion Defi, Inc., holding 1,125,785 shares of common stock.

Forsakringsaktiebolaget Avanza Pension has reported a 10.19% beneficial ownership stake in Hyperion DeFi, Inc., holding 863,087 shares of common stock.

Forsakringsaktiebolaget Avanza Pension has reported a 9.94% beneficial ownership stake in Hyperion DeFi's common stock.

Forsakringsaktiebolaget Avanza Pension, a Swedish insurance company, has reported a 10.11% beneficial ownership stake in Hyperion DeFi.

Forsakringsaktiebolaget Avanza Pension, a Swedish insurance company, has disclosed a 5.62% beneficial ownership stake in Hyperion DeFi.